Free shipping on all orders over $ 500

Trastuzumab Emtansine

Cat. No. M40546

All AbMole products are for research use only, cannot be used for human consumption.

Trastuzumab Emtansine Structure
Synonym:

PRO132365; T-DM 1

Size Price Availability Quantity
5mg USD 1500 In stock
10mg USD 2500 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Trastuzumab Emtansine is a HER2-targeting antibody-drug concatenation (ADC) that can be used in studies related to HER2-positive metastatic breast cancer.

Chemical Information
CAS Number 1018448-65-1
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Javier Cortés et al. N Engl J Med. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

[2] Francis W Hunter et al. Br J Cancer. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

[3] Mark Barok et al. Breast Cancer Res. Trastuzumab emtansine: mechanisms of action and drug resistance

Related Antibody-Drug Conjugates (ADCs) Products
Talacotuzumab-MMAE

Talacotuzumab-MMAE is an antibody-drug conjugate (ADC) targeting IL-3Ra / CD123. Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody.

Enfortumab vedotin-ejfv

Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate (ADC) for the management of urothelial carcinoma. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE via a protease-cleavable maleimidocaproylvaline-citrulline linker.

Vandortuzumab vedotin

Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.

Farletuzumab MMAE

Farletuzumab MMAE is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated to MMAE.

Zilovertamab vedotin

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.

  Catalog
Abmole Inhibitor Catalog




Keywords: Trastuzumab Emtansine, PRO132365; T-DM 1 supplier, Antibody-Drug Conjugates (ADCs), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.